Recombinant oncolytic vaccinia virus and its application

By constructing recombinant oncolytic vaccinia virus, inserting the synonymous mutant gene of 4-1BBL and deleting the TK gene, the high expression and safety of 4-1BBL on the surface of tumor cells was achieved, and the side effects of tumor immunotherapy poisoning in the prior art were solved and Detection problems improve the safety and monitoring capabilities of treatment.

CN117004579BActive Publication Date: 2024-11-15SUZHOU ONLYV BIOTECHNOLOGY LTD CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310781871.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-29
Publication Date
2024-11-15
Estimated Expiration
2043-06-29

Smart Images

  • Figure CN117004579B_ABST
    Figure CN117004579B_ABST
Patent Text Reader

Abstract

The present invention provides a recombinant oncolytic vaccinia virus, which can be operably inserted into an exogenous gene after a synonymous mutation capable of expressing 4-1BBL, and provides its application in the preparation of a drug for preventing or treating tumors and cancer. Beneficial effects are: based on the recombinant vaccinia virus VV-mH4-1BBL of synonymous mutations, the original oncolytic effect of the oncolytic virus and the initiation and enhancement of anti-tumor immune response are retained, and safety is improved by deleting the TK gene; 4-1BBL is highly expressed on the surface of tumor cells, so that 4-1BBL can be made to enhance anti-tumor immunity in a manner that stimulates 4-1BB+ immune cells (including T cells) in the tumor microenvironment, and 4-1BBL is also confined to tumor tissue to play a role in a concentrated manner, avoiding potential systemic toxic and side effects; the introduction of synonymous mutation sites allows the virus to detect the expression of therapeutic (exogenous) 4-1BBL genes during treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a recombinant oncolytic vaccinia virus and applications thereof. Background Art

[0002] Stimulating the 4-1BB signal of immune cells can trigger strong and lasting anti-tumor immunity. Currently, 4-1BB-stimulating monoclonal antibodies have entered clinical research, such as urelumab monoclonal antibody and utomilumab monoclonal antibody. When such antibodies are used systemically, due to the small difference between the effective dose and the safe dose, systemic toxic side effects often occur when the anti-tumor immune effect is effectively stimulated, or there are no obvious toxic side effects but the anti-tumor effect is not significant. These contradictory problems have greatly limited its clinical application.

[0003] Soluble 4-1BBL can stimulate 4-1BB signals, which has not been seen in clinical application studies. If used directly systemically, it can strongly enhance the immune response throughout the body and cause serious toxic side effects.

[0004] Oncolytic viruses can selectively infect tumor cells, induce immunogenic death of tumor cells, activate the body's anti-tumor immunity and induce local inflammation to act as immune adjuvants. However, the use of oncolytic viruses alone to treat tumors often results in the rapid elimination of the virus due to the body's antiviral effect. Therefore, it is necessary to enhance the anti-tumor immunity induced by the oncolytic virus after it takes effect in order to induce a strong and lasting anti-tumor effect. Therefore, it is necessary to introduce immune enhancement factors to improve the anti-tumor effect of oncolytic viruses.

[0005] Studies have reported the use of mouse 4-1BBL gene to construct mouse 4-1BBL recombinant oncolytic virus, and the reliability of its effect has been demonstrated through mouse models. However, recent studies have found that the wild-type 4-1BBL gene is commonly expressed in tumor cells such as colorectal cancer, and its encoded product (ie, 4-1BBL molecule) is located inside the cell rather than on the cell surface. Therefore, if the wild-type 4-1BBL gene is used to construct a 4-1BBL recombinant oncolytic virus for treatment, the expression and location of therapeutic 4-1BBL cannot be detected and tracked.

[0006] Oncolytic viruses can selectively infect and cause immunogenic death of tumor cells, thereby triggering the body's anti-tumor immune response, making it a feasible means of tumor immunotherapy and entering the field of tumor immunotherapy drug research and development. However, as a virus itself, oncolytic viruses are easily cleared by the body, and the anti-tumor immunity triggered by oncolytic viruses faces the common problem of being blocked by negative mechanisms such as immune checkpoints. Therefore, the overall design idea in this field is to construct a recombinant oncolytic virus, retain the advantages of the original oncolytic virus, avoid its weaknesses, and then recombinantly introduce immune enhancement factors to overcome the negative immune mechanism and trigger the body's safe, effective, systemic and lasting anti-tumor immunity.

[0007] The co-stimulatory molecule ligand 4-1BBL acts on the 4-1BB molecules on the surface of T cells, NK cells, DCs, etc., that is, it strongly promotes the body's anti-tumor immunity through the 4-1BB / 4-1BBL pathway. Therefore, biological agents developed with the 4-1BB / 4-1BBL pathway as a stimulating target may become new anti-tumor drugs. Stimulating 4-1BB monoclonal antibodies and 4-1BBL recombinant oncolytic viruses are important biological agents developed in this field, but their shortcomings restrict their future applications and need to be improved.

[0008] The stimulatory 4-1BB monoclonal antibody can activate the strong anti-tumor effect produced by the 4-1BB / 4-1BBL pathway. However, the difference between the monoclonal antibody doses used for effective anti-tumor effects and toxic side effects is small, that is, the safe dose range is small. Therefore, the natural ligand 4-1BBL was selected as an immune activator of the 4-1BB molecule to provide a natural stimulation method to activate the 4-1BB signal. In addition, if soluble 4-1BBL is used directly to treat tumors, toxic side effects may occur due to the systemic effects of cytokines.

[0009] However, existing studies have shown that 4-1BBL molecules are commonly found inside tumor cells such as colorectal cancer and pancreatic cancer, but are not expressed on the cell membrane. In this way, tumor cells can avoid stimulating the 4-1BB molecules on the surface of immune cells. This is a tumor immune escape mechanism. For example, using the natural ligand 4-1BBL to construct a recombinant oncolytic virus can express 4-1BBL on the surface of tumor cells and stimulate anti-tumor immunity. However, in future treatments, it will be extremely difficult to distinguish whether the 4-1BBL gene of the tumor tissue comes from the tumor tissue itself or the therapeutic 4-1BBL recombinant oncolytic virus, which will make it extremely difficult to monitor and judge the efficacy. Summary of the invention

[0010] In view of the above-mentioned technical limitations, the present invention proposes a recombinant oncolytic vaccinia virus and its application, establishes a new 4-1BB signal stimulation method, retains the immune effect of 4-1BBL stimulating 4-1BB signal, improves its safety of use, and provides a new biological preparation that can detect and monitor the treatment process and efficacy, overcoming the shortcomings and defects mentioned in the background technology.

[0011] To achieve the above object, the present invention adopts the following technical solutions:

[0012] The inventive point of the present invention is to provide a recombinant oncolytic vaccinia virus, into which a synonymously mutated foreign gene capable of expressing 4-1BBL can be operably inserted.

[0013] Optionally, in the above-mentioned recombinant oncolytic vaccinia virus, the exogenous gene is inserted into the vaccinia virus TK gene.

[0014] Optionally, in the above-mentioned recombinant oncolytic vaccinia virus, the DNA sequence of the exogenous gene is shown as SEQ ID No.1-SEQ ID No.3.

[0015] The applicant has listed the gene sequences after these three synonymous mutations, but they cannot limit the scope of the technology of the present invention. In fact, as long as the final encoded polypeptide / amino acid / protein sequence is the same (with the same or similar effects), synonymous mutations at any one or several sites are feasible.

[0016] The sequence of SEQ ID No.1 (540T mutated to C) is:

[0017] atggaatacgcctctgacgcttcactggaccccgaagccccgtggcctcccgcgccccgcgctcgcgcctgccgcgtactgccttgggccctggtcgcggggctgctgctgctgctgctgctcgctgccgcctgcgccgtcttcctcgcctgcccctgggccgtgtccggggctcgcgcctcgcccggctccgcggccagcccgagactccgcgagggtcccgagctttcgcccgacgatcccgccggcctcttggacctgcggcagggcatgtttgcgcagctggtggcccaaaatgttctgctgatcgatgggcccctgagctggtacagtgacccaggcctggcaggcgtgtccctgacggggggcctgagctacaaagaggacacgaaggagctggtggtggccaaggctggagtctactatgtcttctttcaactagagctgcggcgcgtggtggccggcgagggctcaggctccgtttcacttgcgctgcacctgcagccactgcgctctgctgctggggccgccgccctggcCttgaccgtggacctgccacccgcctcctccgaggctcggaactcggccttcggtttccagggccgcttgctgcacctgagtgccggccagcgcctgggcgtccatcttcacactgaggccagggcacgccatgcctggcagcttacccagggcgccacagtcttgggactcttccgggtgacccccgaaatcccagccggactcccttcaccgaggtcggaataa。

[0018] The sequence of SEQ ID No.2 (468G mutated to A) is:

[0019] atggaatacgcctctgacgcttcactggaccccgaagccccgtggcctcccgcgccccgcgctcgcgcctgccgcgtactgccttgggccctggtcgcggggctgctgctgctgctgctgctcgctgccgcctgcgccgtcttcctcgcctgcccctgggccgtgtccggggctcgcgcctcgcccggctccgcggccagcccgagactccgcgagggtcccgagctttcgcccgacgatcccgccggcctcttggacctgcggcagggcatgtttgcgcagctggtggcccaaaatgttctgctgatcgatgggcccctgagctggtacagtgacccaggcctggcaggcgtgtccctgacggggggcctgagctacaaagaggacacgaaggagctggtggtggccaaggctggagtctactatgtcttctttcaactagagctgcggcgcgtggtggccggcgaAggctcaggctccgtttcacttgcgctgcacctgcagccactgcgctctgctgctggggccgccgccctggctttgaccgtggacctgccacccgcctcctccgaggctcggaactcggccttcggtttccagggccgcttgctgcacctgagtgccggccagcgcctgggcgtccatcttcacactgaggccagggcacgccatgcctggcagcttacccagggcgccacagtcttgggactcttccgggtgacccccgaaatcccagccggactcccttcaccgaggtcggaataa。

[0020] The sequence of SEQ ID No.3 (597C mutated to T) is as follows:

[0021] atggaatacgcctctgacgcttcactggaccccgaagccccgtggcctcccgcgccccgcgctcgcgcctgccgcgtactgccttgggccctggtcgcggggctgctgctgctgctgctgctcgctgccgcctgcgccgtcttcctcgcctgcccctgggccgtgtccggggctcgcgcctcgcccggctccgcggccagcccgagactccgcgagggtcccgagctttcgcccgacgatcccgccggcctcttggacctgcggcagggcatgtttgcgcagctggtggcccaaaatgttctgctgatcgatgggcccctgagctggtacagtgacccaggcctggcaggcgtgtccctgacggggggcctgagctacaaagaggacacgaaggagctggtggtggccaaggctggagtctactatgtcttctttcaactagagctgcggcgcgtggtggccggcgagggctcaggctccgtttcacttgcgctgcacctgcagccactgcgctctgctgctggggccgccgccctggctttgaccgtggacctgccacccgcctcctccgaggctcggaactcggccttcggtttTcagggccgcttgctgcacctgagtgccggccagcgcctgggcgtccatcttcacactgaggccagggcacgccatgcctggcagcttacccagggcgccacagtcttgggactcttccgggtgacccccgaaatcccagccggactcccttcaccgaggtcggaataa。

[0022] Optionally, for the recombinant oncolytic vaccinia virus described above, the amino acid sequence of the foreign gene is as shown in SEQ ID No.4.

[0023] The sequence of SEQ ID No.4 is:

[0024] MEYASDASLDPEAPWPPARARACRVLPWALVAGLLLLLLLAAACAVFLACPWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYK EDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPPSPRSE.

[0025] Optionally, in the above-mentioned recombinant oncolytic vaccinia virus, the exogenous gene is connected via an IRES sequence.

[0026] IRES is a ribosome entry site and is just one of the linker sequences that can be used.

[0027] Optionally, in the above-mentioned recombinant oncolytic vaccinia virus, the IRES sequence is shown as SEQ ID No.5.

[0028] The sequence of SEQ ID No.5 is:

[0029] .

[0030] The second inventive point of the present invention is to provide a pharmaceutical composition, which includes the above-mentioned recombinant oncolytic vaccinia virus, a pharmaceutically acceptable carrier and a pharmaceutical excipient.

[0031] Optionally, the pharmaceutical composition is administered by direct injection and / or combined with endoscopic injection; the endoscope is preferably a laparoscope, a choledochoscope, a thoracoscope, a colonoscope and a neuroendoscope.

[0032] The third inventive point of the present invention is to provide the use of the above-mentioned recombinant oncolytic vaccinia virus and the above-mentioned pharmaceutical composition in the preparation of drugs for preventing or treating tumors and / or cancers.

[0033] Optionally, in the above-mentioned application, the tumor and / or cancer is a solid tumor, preferably a cold tumor and / or a hot tumor, and its histological type includes but is not limited to pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, gastric cancer, esophageal cancer, brain glioma, ovarian cancer, cervical cancer, prostate cancer, kidney cancer, lung cancer, breast cancer, multiple myeloma, lymphoma, and melanoma.

[0034] The key technical points and advantages of the present invention are:

[0035] 1. A human 4-1BBL gene sequence with synonymous mutations, which can be used to detect and monitor the expression and distribution of therapeutic (exogenous) 4-1BBL in tumor patients after treatment with recombinant vaccinia virus VV-mH4-1BBL;

[0036] 2. Recombinant vaccinia virus VV-mH4-1BBL based on the human 4-1BBL gene sequence with synonymous mutations. This recombinant virus retains the original oncolytic effect of the oncolytic virus, initiating anti-tumor immune response, and enhancing the immune response as an adjuvant. It also makes it safer on the basis of its original good safety by deleting the TK gene. The recombinant vaccinia virus VV-mH4-1BBL achieves high expression of 4-1BBL on the surface of tumor cells in the tumor microenvironment, and achieves 4-1BBL to stimulate 4-1BB signals of 4-1BB+ immune cells (including T cells) in the tumor microenvironment to enhance anti-tumor immunity. It also confines 4-1BBL to tumor tissues to concentrate its effect, avoiding the potential systemic toxic side effects caused by the systemic use of stimulatory 4-1BB monoclonal antibodies or soluble 4-1BBL to treat tumors.

[0037] Compared with other oncolytic viruses, vaccinia virus has its own characteristics:

[0038] 1. It was once used on a large scale to prevent smallpox in the human population, and its safety has been proven;

[0039] 2. The weak expression / no expression of TK gene in normal cells and the strong expression in many tumor cells determine that VV is almost not expressed in normal cells after TK gene knockout, indicating that the product modified with VV as the parent virus has extremely high safety.

[0040] The present invention constructs a human 4-1BBL synonymous mutation gene (a synonymous mutation is a mutation of a certain base pair in a DNA fragment that does not change the encoded amino acid), and on this basis constructs a human 4-1BBL synonymous mutation gene recombinant oncolytic poxvirus VV-mH4-1BBL, which not only retains the original oncolytic effect of the oncolytic virus, the initiation of anti-tumor immunity, and the role characteristics and advantages of enhancing immune response as an adjuvant, but also makes it safer on the basis of its original good safety by deleting the TK gene; through the recombinant vaccinia virus VV-mH4-1BBL, 4-1BBL is highly expressed on the surface of tumor cells in the tumor microenvironment, and 4-1BBL stimulates 4-1BB signals of 4-1BB+ immune cells (including T cells) in the tumor microenvironment to enhance anti-tumor immunity, and 4-1BBL is confined to the tumor tissue to play a concentrated role, thereby avoiding the potential systemic toxic side effects caused by the systemic use of stimulating 4-1BB monoclonal antibodies or soluble 4-1BBL to treat tumors.

[0041] The application of mH4-1BBL in the preparation of tumor drugs has the following trends and effects:

[0042] 1. Application of mH4-1BBL to improve the anti-tumor immune status of tumor microenvironment:

[0043] The interaction between tumor cells and anti-tumor immunity jointly determines the occurrence and progression of tumors. The number and functional status of immune cells (especially dendritic cells DC and T cells) in the tumor microenvironment is one of the key factors affecting the effect of tumor immunotherapy and patient outcomes.

[0044] mH4-1BBL mainly dissolves local tumor tissue through the characteristics of oncolytic viruses, initiates immune response, and establishes an inflammatory environment of tumor immunity locally in the tumor; by expressing the mH4-1BBL encoding protein and expressing it on the surface of tumor cells, it enhances and maintains the anti-tumor functional state of immune cells such as DC and T cells in the "inflammatory environment" of tumor tissue. Therefore, VV-mH4-1BBL has an effect on tumor tissues under different immune states: based on the immunophenotyping perspective of the tumor microenvironment, VV-mH4-1BBL can be used for "immune inflammatory" tumor tissues (i.e., "hot tumors" with infiltration of immune cells such as T cells), making "hot tumors" even "hotter", that is, further enhancing the number and activity of immune cells in the tumor microenvironment; VV-mH4-1BBL can be used for "immune desert" tumor tissues (i.e., "cold tumors" with a lack of immune cells such as T cells inside and around the tumor tissue), converting "cold tumors" into "hot tumors", that is, promoting the infiltration of immune cells such as T cells into tumor tissues, while enhancing their anti-tumor activity, and also creating conditions for combined immunotherapy such as PD-1 monoclonal antibodies; VV-mH4-1BBL can be used for "immune exempt" tumor tissues (immune cells such as T cells exist on the periphery of tumor tissues but cannot infiltrate into tumor tissues), not only promoting immune cells to break through various barriers and enter tumor tissues, but also promoting the anti-tumor function of immune cells.

[0045] 2. VV-mH4-1BBL treats superficial and deep tumors by direct injection and combined with endoscopic injection:

[0046] Based on the application (dosage) method, VV-mH4-1BBL can be used for a series of solid tumors on the surface of the body, such as melanoma, by direct intratumoral injection. VV-mH4-1BBL can also be accurately injected into deep solid tumors through laparoscopes, choledochoscopes, thoracoscopes, colonoscopes, neuroendoscopes, etc., based on clear observation of the tumor, to directly dissolve tumor cells while stimulating anti-tumor immune responses.

[0047] 3. VV-mH4-1BBL is used in drugs for the treatment of solid tumors such as colorectal cancer, pancreatic cancer and melanoma:

[0048] From the perspective of tumor type, since VV-mH4-1BBL works by directly dissolving tumors and activating and enhancing the efficacy of immune cells such as T cells, VV-mH4-1BBL can be used through the above-mentioned administration method to treat pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, gastric cancer, esophageal cancer, brain glioma, ovarian cancer, cervical cancer, prostate cancer, kidney cancer, lung cancer, breast cancer, multiple myeloma, lymphoma, melanoma, etc. of various clinical stages.

[0049] In fact, VV-mH4-1BBL can be used to treat all types of solid tumors, and the applicant has conducted a large number of related experiments to prove it. However, considering the space limitation, only representative verification experiments of colorectal cancer, pancreatic cancer and melanoma are listed in this application. This experimental data cannot limit the scope of VV-mH4-1BBL's effect on all types of solid tumors.

[0050] The present invention constructs a synonymous mutation gene mH4-1BBL, and then constructs a recombinant vaccinia virus VV-mH4-1BBL. In order to express the 4-1BBL molecule with a strong anti-tumor immune function at a high level on the surface of tumor cells, and to detect and monitor the expression of therapeutic 4-1BBL, the synonymous mutation gene mH4-1BBL of 4-1BBL is obtained by molecular design and synthesis of synonymous mutation primers, and the 540T base is changed to the 540C base by PCR; and then mH4-1BBL is recombined into the vaccinia virus genome to construct a new recombinant vaccinia virus containing the mH4-1BBL gene sequence, named VV-mH4-1BBL. VV-mH4-1BBL not only retains the oncolytic properties, but also expresses a large amount of the encoded protein of the mH4-1BBL gene while rapidly replicating, and is expressed on the surface of tumor cells. The recombinant vaccinia virus VV-mH4-1BBL, as a virus itself, can play a direct oncolytic role and then initiate anti-tumor immunity. The protein 4-1BBL encoded by the mH4-1BBL gene it carries is confined to tumor tissues and plays a therapeutic role in enhancing anti-tumor immunity.

[0051] If an stimulating anti-human 4-1BB monoclonal antibody or a soluble 4-1BBL acting as a 4-1BB signaling agonist is used for tumor immunotherapy, there may be a potential risk of systemic toxic side effects. The protein 4-1BBL molecule encoded by the mH4-1BBL gene carried by VV-mH4-1BBL is confined to the tumor microenvironment to play a role, which can not only avoid potential systemic side effects of 4-1BBL, but also achieve high-level expression of 4-1BBL in local tumor tissues, exerting a stronger local anti-tumor effect. This is the advantage of the recombinant vaccinia virus VV-mH4-1BBL. In addition, while constructing the recombinant virus, the thymidine kinase (TK) gene of the vaccinia virus was deleted to make it safer and further enhance the selectivity of infected tumor cells.

[0052] The present invention well achieves the technical effect of constructing synonymous mutation genes and recombinant oncolytic viruses, retaining the advantages of the original oncolytic viruses and avoiding their weaknesses. In the present invention, the 540T base of the wild-type human 4-1BBL coding sequence is mutated to a 540C base to construct a synonymous mutation gene mH4-1BBL. Then mH4-1BBL is introduced into vaccinia virus VV by homologous recombination to establish a recombinant vaccinia virus VV-mH4-1BBL. Recombinant vaccinia virus VV-mH4-1BBL is applied to drugs for tumor immunotherapy, while infecting tumor cells and obtaining the effect of dissolving tumor cells and promoting the local inflammatory environment of the tumor, expressing the 4-1BBL encoding fusion protein expressed on the cell surface, so that the 4-1BBL molecular substance is concentrated and confined to the tumor microenvironment, while promoting anti-tumor immune response, avoiding potential systemic toxic and side effects and other adverse reactions, breaking through the bottleneck of tumor immunotherapy in which anti-tumor immune cells are not easy to enter tumor tissues and anti-tumor immunity is easily suppressed by negative immunosuppression in patients.

[0053] The present invention recombines 4-1BBL into an oncolytic virus, so that 4-1BBL can play a role locally in the tumor microenvironment and avoid systemic effects. Therefore, the present invention better avoids the potential danger of serious loss of control of the super-strong activation of 4-1BB signal caused by artificially prepared antibodies, and also avoids the systemic toxic side effects that may be caused by directly using soluble 4-1BBL.

[0054] The synonymous mutant 4-1BBL recombinant poxvirus constructed by the present invention can monitor the expression of exogenous 4-1BBL, monitor and evaluate the therapeutic effect by molecular biological means such as simple molecular gene sequencing without changing the 4-1BBL protein sequence. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 Shown are the gene segments introduced into the recombinant vector PV-1 and a schematic diagram of the structure of the PV-1 vector.

[0056] Figure 2 Shown is a schematic diagram of the preparation of the F1-2 fragment during site-directed mutagenesis of human 4-1BBL.

[0057] Figure 3 Shown is a schematic diagram of the preparation of the F1-1 fragment during site-directed mutagenesis of human 4-1BBL.

[0058] Figure 4 Shown is a schematic diagram for connecting site-directed mutagenesis fragments to construct a synonymous mutant full-length human 4-1BBL (mH4-1BBL) gene.

[0059] Figure 5 Shown is a gel electrophoresis diagram of PCR products that introduced synonymous mutations into the human 4-1BBL gene, where: Figure 5 A is the gel electrophoresis result of PCR products from fragment F1-1 to fragment F3-2, Figure 5 B is the gel electrophoresis result of PCR products of mH4-1BBL, mH4-1BBL-2, and mH4-1BBL-3 after synonymous mutations.

[0060] Figure 6 Shown is flow cytometry detection of the expression of 4-1BBL molecules on the cell surface of colon cancer cells HCT-116 after infection with VV-ΔTK, VV-mH4-1BBL, VV-mH4-1BBL-2 and VV-mH4-1BBL-3.

[0061] Figure 7 Shown is the human 4-1BBL gene sequence expressed in human colorectal cancer cell lines detected by RT-PCR and gene sequencing.

[0062] Figure 8 The figure shows the alignment of human 4-1BBL gene sequences expressed by human colorectal cancer cell lines using the BLAST program on the NCBI website.

[0063] Fig. 9 Shown is the human 4-1BBL gene sequence expressed after VV-mH4-1BBL infected human colon cancer cell lines detected by RT-PCR and gene sequencing.

[0064] Fig.10 Shown is the human 4-1BBL gene sequence expressed after VV-mH4-1BBL-2 infected human colon cancer cell lines detected by RT-PCR and gene sequencing.

[0065] Fig.11 Shown is the human 4-1BBL gene sequence expressed after VV-mH4-1BBL-3 infected human colon cancer cell lines detected by RT-PCR and gene sequencing.

[0066] Fig.12Shown are the gene segments introduced into the recombinant vector PV-1 and a schematic diagram of the structure of the PV-1 vector.

[0067] Fig.13 The figure shows the mouse 4-1BBL gene sequence carried by the PV-4-1BBL recombinant vector identified by gene sequencing.

[0068] Fig.14 Shown are the alignment results of the mouse 4-1BBL gene sequences carried by the PV-4-1BBL recombinant vector.

[0069] Fig.15 It shows that after MC-38 cells were infected with the recombinant oncolytic poxvirus VV-ΔTK-4-1BBL, high expression of the 4-1BBL gene was detected by RT-PCR.

[0070] Fig.16 It shows that after MC-38 cells were infected with the recombinant oncolytic poxvirus VV-ΔTK-4-1BBL, the expression of 4-1BBL molecules on the cell surface was detected by immunofluorescence labeling and flow cytometry.

[0071] Fig.17 The figure shows the virus titer method to detect the proliferation ability of VV-ΔTK-4-1BBL in different tumor cells; A: mouse pancreatic cancer cell line LTPA; B: mouse melanoma cell line B16-F10; C: mouse pancreatic cancer cell line Panc02 / Luc; D: mouse colorectal cancer cell line MC-38.

[0072] Fig.18 The figure shows the MTT method to detect the killing ability of VV-ΔTK-4-1BBL on different tumor cells in vitro; A: mouse pancreatic cancer cell line LTPA; B: mouse melanoma cell line B16-F10; C: mouse pancreatic cancer cell line Panc02 / Luc; D: mouse colorectal cancer cell line MC-38.

[0073] Fig.19 Shown is the mouse 4-1BBL gene sequence expressed in mouse colon cancer cells detected by gene sequencing.

[0074] Fig. 20 Shown is the alignment result of mouse 4-1BBL gene sequence obtained by RT-PCR.

[0075] Fig.21 Shown is the 4-1BBL gene sequence expressed in mouse colon cancer cells in the VV-△TK-4-1BBL treatment group detected by gene sequencing.

[0076] Fig. 22 Shown is the alignment result of mouse 4-1BBL gene sequence obtained by RT-PCR.

[0077] Fig.23 Shown are the gross observation of spleen and the comparison of spleen weight and number of cells in spleen after VV-ΔTK-4-1BBL treatment in MC-38 tumor-bearing mice; Fig.23 A is the comparison result of spleen weight, Fig.23 B is the comparison result of the number of cells in the spleen.

[0078] Fig.24 Shown are the percentages of CD3+T, CD8+T, and CD4+T cells in the spleen after VV-ΔTK-4-1BBL treatment; Fig.24 A is the percentage change of CD3+T cells in spleen, Fig.24 B is the percentage change of CD8+T cells in spleen, Fig.24 C is the change in the percentage of CD4+T cells in the spleen.

[0079] Fig.25 The effect of VV-ΔTK-4-1BBL treatment on PD-1 expression in CD4+T and CD8+T cells in spleen tissue is shown. Fig.25 A is the results of immunofluorescence staining and flow cytometry analysis after VV-ΔTK-4-1BBL treatment. Fig.25 B is the comparison result of PD-1 expression of CD8+T cells in spleen measured by flow cytometry after VV-ΔTK-4-1BBL treatment. Fig.25 C is the comparison result of PD-1 expression of CD4+T cells in the spleen measured by flow cytometry after VV-ΔTK-4-1BBL treatment.

[0080] Fig.26 Shown are the percentages of CD3+T, CD8+T, and CD4+T cells in tumor tissues after VV-ΔTK-4-1BBL treatment, among which, Fig.26 A is the percentage of CD3+T cells, Fig.26 B is the percentage of CD8+T cells, Fig.26 C is the percentage of CD4+ T cells.

[0081] Fig. 27 Shown are the changes in immune molecules in tumor tissue after VV-ΔTK-4-1BBL treatment, among which, Fig. 27 A is the change of the immune molecule Perforin. Fig. 27 B is the change of immune molecule granzyme B, Fig. 27 C is the change of immune molecule IFN-γ, Fig. 27 D is the change of immune molecule IL-1β, Fig. 27 E is the change of immune molecule TNF-α, Fig. 27 F shows the changes of immune molecule TGF-β.

[0082] Fig.28 Shown is a comparison of the efficacy of recombinant vaccinia virus in treating the mouse peritoneal tumor model of colorectal cancer.

[0083] Fig.29 Shown is the observation of survival time in the MC-38 peritoneal mouse tumor model treated with recombinant oncolytic poxvirus VV-ΔTK-4-1BBL combined with PD-1 / PD-L1 blockade. DETAILED DESCRIPTION

[0084] In order to make the purpose, technical solution and advantages of the present invention more clear, the present invention is further described in detail below. However, it should be understood that the description herein is only used to explain the present invention and is not used to limit the scope of the present invention.

[0085] Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention, and the terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The reagents and instruments used herein are all commercially available, and the characterization means involved can refer to the relevant descriptions in the prior art, which will not be repeated herein.

[0086] In order to further understand the present invention, the present invention is further described in detail below in conjunction with the best embodiment.

[0087] The synonymous mutant gene 4-1BBL (mH4-1BBL) recombinant vaccinia virus, codenamed VV-mH4-1BBL, is a recombinant vaccinia virus obtained by inserting the gene sequence of the synonymous mutant gene mH4-1BBL and related regulatory elements after the 81001bp position of the vaccinia virus parent genome (the gene sequence is based on GenBank: AY243312.1), wherein the gene sequence inserted into the vaccinia virus parent genome is shown in SEQ ID No.22.

[0088] The synonymous mutant gene mH4-1BBL was obtained by selecting the 540th base of its coding sequence based on the wild-type human 4-1BBL gene sequence (the gene sequence is based on the NCBI Reference Sequence: NM_003811.4 coding sequence), and performing synonymous mutation by PCR by designing primers.

[0089] The genetic information of the VV-mH4-1BBL recombinant virus is:

[0090] 1. The gene sequence of the vaccinia virus parent used to construct the VV-mH4-1BBL recombinant oncolytic virus is based on GenBank: AY243312.1, and the gene sequence of the vaccinia virus parent mentioned in the following statements is based on this.

[0091] 2. The synonymous mutant gene mH4-1BBL and related regulatory elements were homologously recombined with the vaccinia virus parent through a recombinant vector (PV-mH4-1BBL). In this process, the mH4-1BBL gene and related regulatory element sequences were inserted after the 81001bp position of the vaccinia virus parent genome, that is, in the middle of the thymidine kinase (TK) gene, which not only destroyed the complete TK gene (knocked out the TK gene), but also achieved the expression of mH4-1BBL. Since the yellow fluorescent protein (YFP) gene (with loxp sequences on both sides of the gene) used for recombinant virus screening is included in the related regulatory elements, the above-mentioned recombinant virus is infected with 293T cells transfected with the Cre gene to delete YFP, thereby obtaining the mH4-1BBL recombinant vaccinia virus in the present invention: VV-mH4-1BBL. Compared with the genome of the parent vaccinia virus (VV), a gene fragment (SEQ ID No. 22) is inserted into the TK gene in the VV-mH4-1BBL genome, and its gene sequence is as follows (the underlined sequence is the mH4-1BBL gene; 3' to 5' direction; other sequences are regulatory elements such as promoters):

[0092] SEQ ID No.22:

[0093] 5'-agatcgataaaaattaattattacccgggtaccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaa cataaaatgaatgcaattgttgttgttaac TTATTCCGACCTCGGT GAAGGGAGTCCGGCTGGGATTTCGGGGGTCACCCGGAAGAGTCCCAAGACTGTGGCGCCCTGGGTAAGCTGCCAGG CATGGCGTGCCCTGGCCTCAGTGTGAAGATGGACGCCCAGGCGCTGGCCGGCACTCAGGTGCAGCAAGCGGCCCTG GAAACCGAAGGCCGAGTTCCGAGCCTCGGAGGAGGCGGGTGGCAGGTCCACGGTCAAAGCCAGGGCGGCGGCCCCA GCAGCAGAGCGCAGTGGCTGCAGGTGCAGCGCAAGTGAAACGGAGCCTGAGCCCTCGCCGGCCACCACGCGCCGCA GCTCTAGTTGAAAGAAGACATAGTAGACTCCAGCCTTGGCCACCACCAGCTCCTCGTGTCCTCTTTGTAGCTCAG GCCCCCCGTCAGGGACACGCCTGCCAGGCCTGGGTCACTGTACCAGCTCAGGGGCCCATCGATCAGCAGAACATTT TGGGCCACCAGCTGCGCAAACATGCCCTGCCGCAGGTCCAAGAGGCCGGCGGGATCGTCGGGCGAAAGCTCGGGAC CCTCGCGGAGTCTCGGGCTGGCCGCGGAGCCGGGCGAGGCGAGCCCCGGACACGGCCCAGGGGCAGGCGAGGAA GACGGCGCAGGCGGCAGCGAGCAGCAGCAGCAGCAGCAGCCCCGCGACCAGGGCCCAAGGCAGTACGCGGCAGGCG CGAGCGCGGGGCGCGGGAGGCCACGGGGCTTCGGGGTCCAGTGAAGCGTCAGAGGCGTATTCCATCCTGCAGGGCCGGCCATTATCATCGTGTTTTTCAAAGGAAAACCACGTCCCCGTGGTTCGGGGGGCCTAGACGTTTTTTAACCTCGACTAAACACATGTAAAGCATGTGCACCGAGGCCCCAGATCAGATCCCATACAATGGGGTACCTTCTGGGCATCCTTCAGCCCCTTGTTGAATACGCTTGAGGTGAGCCATTTGACTCTTTCCACAACTATCCAACTCACAACGTGGCACTGGGGTTGTGCCGCCTTTGCAGGTGTATCTTATACACGTGGCTTTTGGCCGCAGAGGCACCTGTCGCCAGGTGGGGGGTTCCGCTGCCTGCAAAGGGTCGCTACAGACGTTGTTTGTCTTCAAGAAGCTTCCAGAGGAACTGCTTCCTTCACGACATTCAACAGACCTTGCATTCCTTTGGCGAGAGGGGAAAGACCCCTAGGAATGCTCGTCAAGAAGACAGGGCCAGGTTTCCGGGCCCTCACATTGCCAAAAGACGGCAATATGGTGGAAAATAACATATAGACAAACGCACACCGGCCTTATTCCAAGCGGCTTCGGCCAGTAACGTTAGGGGGGGGGGAGGGAGAGGGGCGGGCGCGCCTTAAGTCGACttcgagcttatttatattccaaaaaaaaaaaataaaatttcaatttttaagctttcactaattccaaacccacccgctttttatagtaagtttttcacccataaataataaatacaataattaatttctcgtaaaagtagaaaatatattctaatttattgcacggtaaggaagtagatcataactcgagataacttcgtataatgtatgctatacgaagttatgcggccgcttcctcgctcactgacgctagcgccctatagtgagtcgtattacagatcc-3’.

[0094] The VV-mH4-1BBL of the present invention is established by the following method:

[0095] 1) Construction of synonymous mutation gene mH4-1BBL: Using the wild-type human 4-1BBL gene (the gene sequence is based on the coding sequence of NCBI Reference Sequence: NM_003811.4) as a template, the 540th base of its coding sequence was used as the center to design and synthesize synonymous mutation primers. The 540T base was changed to 540C base by PCR, and only the polypeptide product encoded by it was changed. The 4-1BBL gene after the synonymous mutation was named mH4-1BBL gene;

[0096] 2) Introducing restriction enzyme sites on both wings of the gene mH4-1BBL: SdaI and HpaI restriction enzyme sites were introduced on both wings of the mH4-1BBL gene by PCR to separate the gene fragment;

[0097] 3) Preparation of sticky ends of vaccinia virus VV homologous recombination vector: Use SdaI and HpaI to cut the VV homologous recombination vector PV-1 (containing yellow fluorescent YFP sequence) and separate the plasmid fragment;

[0098] 4) Ligation of the gene mH4-1BBL with the cohesive ends of the VV homologous recombination vector PV-1: ligation of the recovered products in step 2) and step 3);

[0099] 5) Transform competent cells and screen positive clones: The ligation product of step 4) was co-incubated with competent E. coli. After expansion, the recombinant plasmid was extracted and sequenced to confirm that the gene mH4-1BBL was correctly cloned into the homologous recombination vector PV-1 and named PV-mH4-1BBL;

[0100] 6) The gene mH4-1BBL is recombined into the VV genome: while VV is infected and replicated, PV-mH4-1BBL undergoes homologous recombination with it; the mH4-1BBL gene fragment and the yellow fluorescent YFP sequence are simultaneously homologously recombined into the VV genome to form a recombinant virus; at the same time, since the position where mH4-1BBL is inserted into the VV genome is inside the TK gene, the TK gene is destroyed (i.e., the TK gene is deleted); then, a single clone of the recombinant VV is screened to obtain a high-purity recombinant VV;

[0101] 7) The obtained high-purity recombinant VV was infected with 293T cells expressing cre enzyme, the YFP gene in the recombinant VV genome was excised, and then the monoclonal recombinant VV was screened to obtain the seeds of the target recombinant VV and purify them. Gene sequencing analysis confirmed that the correct mH4-1BBL gene was recombined into VV, and the synonymous mutant gene mH4-1BBL recombinant oncolytic vaccinia virus was obtained, which was named VV-mH4-1BBL.

[0102] The present invention provides a synonymous mutation 4-1BBL recombinant vaccinia virus, namely VV-mH4-1BBL, for use in the preparation of anti-tumor drugs. The recombinant vaccinia virus VV-mH4-1BBL can be used alone in the preparation of anti-tumor drugs, or in combination with other anti-tumor drugs or methods.

[0103] Among them, the recombinant vaccinia virus VV-mH4-1BBL can be used to prepare drugs or products for treating "immune inflammatory" tumor tissue, "immune desert" tumor tissue, and "immune exempt" tumor tissue.

[0104] Among them, the recombinant vaccinia virus VV-mH4-1BBL can be used to prepare drugs and products for treating superficial tumors and deep tumors through direct injection and combined endoscopic injection;

[0105] Surface tumors include, but are not limited to, solid tumors such as melanoma that exist on the surface of the body.

[0106] Combined endoscopic injection therapy includes but is not limited to precise intratumoral injection therapy of deep solid tumors based on clear observation of the tumor mass through laparoscope, choledochoscope, thoracoscope, colonoscope, neuroendoscope, etc.

[0107] Among them, the recombinant vaccinia virus VV-mH4-1BBL can be used to prepare drugs and products for treating tumors of various clinical stages, including but not limited to pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, gastric cancer, esophageal cancer, brain glioma, ovarian cancer, cervical cancer, prostate cancer, kidney cancer, lung cancer, breast cancer, multiple myeloma, lymphoma, and melanoma.

[0108] The application of the synonymous mutant gene mH4-1BBL, through gene sequencing of a series of tumors such as colorectal cancer cells, shows that tumor cells themselves express wild-type 4-1BBL, but its expression product 4-1BBL molecules are located inside the cells and not expressed on the cell surface. In the process of using the synonymous mutant gene mH4-1BBL to implement therapeutic intervention in tumor cells, its expression level can be detected at the gene level and detected for the treatment process and efficacy monitoring.

[0109] Example 1

[0110] Construction of recombinant oncolytic vaccinia virus: Through PCR site-directed mutagenesis, the wild-type human 4-1BBL gene (the gene sequence is based on the coding sequence of NCBI Reference Sequence: NM_003811.4) was mutated to a synonymous codon (synonymous mutation means: the nucleotide sequence of the gene codon changes, but the amino acid encoded by it does not change). The human 4-1BBL after the synonymous mutation was named mh4-1BBL, and mh4-1BBL was recombined into the vaccinia virus genome, and the TK (thymidine kinase) gene was knocked out at the same time to construct a new recombinant vaccinia virus, named VV-mh4-1BBL. VV-mh4-1BBL retains the oncolytic properties of the parent VV, and can express the mh4-1BBL molecule and localize it on the cell membrane surface after infecting tumor cells. The mh4-1BBL molecule has no difference in amino acid sequence from the wild-type 4-1BBL molecule, but at the mRNA level, it can be distinguished whether the 4-1BBL expressed in the tumor tissue after VV-mh4-1BBL treatment is endogenous or exogenous. The mh4-1BBL molecule expressed by oncolytic virus can avoid the potential risks caused by the systemic effects of soluble 4-1BBL when used, and also allows the mh4-1BBL molecule to concentrate in the tumor tissue (tumor microenvironment) to play a therapeutic role in enhancing anti-tumor immunity.

[0111] A recombinant oncolytic vaccinia virus is operably inserted with a synonymous mutated foreign gene capable of expressing 4-1BBL.

[0112] The foreign gene is inserted into the TK gene of vaccinia virus.

[0113] The DNA sequences of the exogenous genes are shown in SEQ ID No.1-SEQ ID No.3.

[0114] The applicant has listed the gene sequences after these three synonymous mutations, but they cannot limit the scope of the technology of the present invention. In fact, as long as the final encoded polypeptide / amino acid / protein sequence is the same (with the same or similar effects), synonymous mutations at any one or several sites are feasible.

[0115] The sequence of SEQ ID No.1 (540T mutated to C) is:

[0116] atggaatacgcctctgacgcttcactggaccccgaagccccgtggcctcccgcgccccgcgctcgcgcctgccgcgtactgccttgggccctggtcgcggggctgctgctgctgctgctgctcgctgccgcctgcgccgtcttcctcgcctgcccctgggccgtgtccggggctcgcgcctcgcccggctccgcggccagcccgagactccgcgagggtcccgagctttcgcccgacgatcccgccggcctcttggacctgcggcagggcatgtttgcgcagctggtggcccaaaatgttctgctgatcgatgggcccctgagctggtacagtgacccaggcctggcaggcgtgtccctgacggggggcctgagctacaaagaggacacgaaggagctggtggtggccaaggctggagtctactatgtcttctttcaactagagctgcggcgcgtggtggccggcgagggctcaggctccgtttcacttgcgctgcacctgcagccactgcgctctgctgctggggccgccgccctggcCttgaccgtggacctgccacccgcctcctccgaggctcggaactcggccttcggtttccagggccgcttgctgcacctgagtgccggccagcgcctgggcgtccatcttcacactgaggccagggcacgccatgcctggcagcttacccagggcgccacagtcttgggactcttccgggtgacccccgaaatcccagccggactcccttcaccgaggtcggaataa。

[0117] The sequence of SEQ ID No.2 (468G mutated to A) is:

[0118] atggaatacgcctctgacgcttcactggaccccgaagccccgtggcctcccgcgccccgcgctcgcgcctgccgcgtactgccttgggccctggtcgcggggctgctgctgctgctgctgctcgctgccgcctgcgccgtcttcctcgcctgcccctgggccgtgtccggggctcgcgcctcgcccggctccgcggccagcccgagactccgcgagggtcccgagctttcgcccgacgatcccgccggcctcttggacctgcggcagggcatgtttgcgcagctggtggcccaaaatgttctgctgatcgatgggcccctgagctggtacagtgacccaggcctggcaggcgtgtccctgacggggggcctgagctacaaagaggacacgaaggagctggtggtggccaaggctggagtctactatgtcttctttcaactagagctgcggcgcgtggtggccggcgaAggctcaggctccgtttcacttgcgctgcacctgcagccactgcgctctgctgctggggccgccgccctggctttgaccgtggacctgccacccgcctcctccgaggctcggaactcggccttcggtttccagggccgcttgctgcacctgagtgccggccagcgcctgggcgtccatcttcacactgaggccagggcacgccatgcctggcagcttacccagggcgccacagtcttgggactcttccgggtgacccccgaaatcccagccggactcccttcaccgaggtcggaataa。

[0119] The sequence of SEQ ID No.3 (597C mutated to T) is:

[0120] atggaatacgcctctgacgcttcactggaccccgaagccccgtggcctcccgcgccccgcgctcgcgcctgccgcgtactgccttgggccctggtcgcggggctgctgctgctgctgctgctcgctgccgcctgcgccgtcttcctcgcctgcccctgggccgtgtccggggctcgcgcctcgcccggctccgcggccagcccgagactccgcgagggtcccgagctttcgcccgacgatcccgccggcctcttggacctgcggcagggcatgtttgcgcagctggtggcccaaaatgttctgctgatcgatgggcccctgagctggtacagtgacccaggcctggcaggcgtgtccctgacggggggcctgagctacaaagaggacacgaaggagctggtggtggccaaggctggagtctactatgtcttctttcaactagagctgcggcgcgtggtggccggcgagggctcaggctccgtttcacttgcgctgcacctgcagccactgcgctctgctgctggggccgccgccctggctttgaccgtggacctgccacccgcctcctccgaggctcggaactcggccttcggtttTcagggccgcttgctgcacctgagtgccggccagcgcctgggcgtccatcttcacactgaggccagggcacgccatgcctggcagcttacccagggcgccacagtcttgggactcttccgggtgacccccgaaatcccagccggactcccttcaccgaggtcggaataa。

[0121] The amino acid sequence of the foreign gene is shown in SEQ ID No. 4.

[0122] The sequence of SEQ ID No. 4 is:

[0123] MEYASDASLDPEAPWPPARARACRVLPWALVAGLLLLLLLAAACAVFLACPWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYK EDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPPSPRSE.

[0124] The foreign gene was linked via the IRES sequence.

[0125] IRES is a ribosome entry site and is just one of the linker sequences that can be used.

[0126] The IRES sequence is shown as SEQ ID No.5.

[0127] The sequence of SEQ ID No.5 is:

[0128] .

[0129] The present invention also provides a pharmaceutical composition, comprising the above-mentioned recombinant oncolytic vaccinia virus, a pharmaceutically acceptable carrier and pharmaceutical excipients.

[0130] The pharmaceutical composition is administered by direct injection and / or combined with endoscopic injection; the endoscope is preferably a laparoscope, a choledochoscope, a thoracoscope, a colonoscope and a neuroendoscope.

[0131] The present invention also provides the use of the above-mentioned recombinant oncolytic vaccinia virus and the above-mentioned pharmaceutical composition in the preparation of a drug for preventing or treating tumors and / or cancers.

[0132] The tumor and / or cancer is a solid tumor, preferably a cold tumor and / or a hot tumor, and its histological type includes but is not limited to pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, gastric cancer, esophageal cancer, brain glioma, ovarian cancer, cervical cancer, prostate cancer, kidney cancer, lung cancer, breast cancer, multiple myeloma, lymphoma, and melanoma.

[0133] Example 2

[0134] Detection of synonymous mutation sites after the synonymous mutation human 4-1BBL recombinant poxvirus infected colorectal cancer cells:

[0135] The biological function of protein molecules depends on their correct amino acid sequence. The base sequence of DNA encodes amino acids through triplet codons. In this process, there is a biological phenomenon of "degenerate codons", that is, an amino acid can be encoded by more than one triplet codon. Therefore, different codons corresponding to the same amino acid are called synonymous codons. These synonymous codons usually have the first and second bases identical, and only the third base is different.

[0136] In view of the above biological mechanism, synonymous mutations can be performed on the codons of the gene DNA sequence encoding a specific protein (changing the third base of the codon and keeping the amino acid encoded by the codon unchanged). This will not affect the amino acid sequence and function of the gene expression product, and the synonymous mutant bases introduced into the cell can be detected by molecular biological methods.

[0137] In this example, a recombinant oncolytic virus expressing a synonymous mutation of the human 4-1BBL gene is constructed. The purpose is to express the 4-1BBL molecule locally in the tumor tissue while exerting the anti-tumor effect of the oncolytic virus itself, promote anti-tumor immunity, and detect the therapeutic (exogenous) 4-1BBL by detecting the synonymous mutation site.

[0138] 1. Construction of recombinant vector carrying synonymous mutation human 4-1BBL gene:

[0139] In order to verify that the mutant human 4-1BBL gene expressed by tumor cells infected with the synonymous mutant human 4-1BBL recombinant poxvirus can be detected by molecular biological methods, the synonymous mutant human 4-1BBL gene was constructed in this example and cloned into the homologous recombination vector PV-1 ( Figure 1 ), the synonymous mutant human 4-1BBL gene was introduced into the vaccinia virus by homologous recombination, and the tk (thymidine kinase) gene was deleted at the same time to obtain the synonymous mutant human 4-1BBL recombinant poxvirus.

[0140] The gene fragment introduced into the recombinant vector PV-1 and the structure of the PV-1 vector are shown in the figure below. Figure 1 shown. Figure 1 In the vector, TK 5' and TK 3' sequences are homologous to part of the vaccinia virus genome sequence and are located on both sides of the target gene sequence. The recombinant vector is constructed and introduced into a host cell infected with wild-type vaccinia virus. The TK 5' and TK 3' sequences can undergo homologous recombination with wild-type vaccinia virus genes, and the gene sequence between TK 5' and TK 3' in the vector is introduced into the vaccinia virus genome to construct a recombinant virus.

[0141] Figure 1 The nouns in are:

[0142] 1) MCS: multiple cloning site, where the target gene can be inserted;

[0143] 2) YFP: yellow fluorescent protein gene;

[0144] 3) IRES: ribosome entry site;

[0145] 4) PV-1: homologous recombination vector;

[0146] 5) PV-mH4-1BBL: a recombinant vector after the mH4-1BBL gene was introduced into the multiple cloning site of the PV-1 vector;

[0147] 6) PV-mH4-1BBL-2: a recombinant vector after the mH4-1BBL-2 gene was introduced into the multiple cloning site of the PV-1 vector;

[0148] 7) PV-mH4-1BBL-3: A recombinant vector in which the mH4-1BBL-3 gene is introduced into the multiple cloning site of the PV-1 vector.

[0149] The above-mentioned mH4-1BBL, mH4-1BBL-2 and mH4-1BBL-3 genes are based on the CDS of the wild-type human 4-1BBL gene (NCBI Reference Sequence: NM_003811.4), and the polypeptide product sequences encoded by mutating the 540th base T to the base C, the 468th base G to the base A, and the 597th base C to the base T, respectively, that is, the 4-1BBL gene after synonymous mutation.

[0150] 2. Preparation of Synonymous Mutation Human 4-1BBL Gene:

[0151] 1. Design and preparation process of synonymous mutation of base 540 T to base 540 C in CDS of human 4-1BBL gene:

[0152] In order to construct a synonymous mutant human 4-1BBL gene based on the coding sequence (CDS) of the wild-type human 4-1BBL gene (H4-1BBL), the CDS of the wild-type human 4-1BBL gene (NCBI Reference Sequence: NM_003811.4) was used as a benchmark, and mutation primers were designed for the 540th T base of its CDS and mutated to a C base by PCR. In the CDS of the human 4-1BBL gene, the codon to which the 540th T base belongs is "GCT" (encoding alanine), and after mutation to "GCC", it still encodes alanine. The designed primers are as follows:

[0153] Pf (SEQ ID No.6):

[0154] 5'-TATAGTCGACATGGAATACGCCTCTGACGCTTC-3' (containing the Sal I restriction enzyme site);

[0155] At the same time, synonymous mutation primers were designed and synthesized with the 540th base of the coding sequence as the center:

[0156] Pr11 (SEQ ID No.7):

[0157] 5'-CGGGTGGCAGGTCCACGGTCAAGGCCAGGGCGGCGGCCCCAGCAGC-3'.

[0158] Using the wild-type human 4-1BBL gene (H4-1BBL) as a template and Pf and Pr11 as primers, fragment F1-2 was obtained by PCR (technical route as shown in Figure 2 PCR product fragments are shown in Figure 5 ).

[0159] In order to construct a synonymous mutant human 4-1BBL gene based on the wild-type human 4-1BBL gene (H4-1BBL), the coding sequence (CDS) of the wild-type human 4-1BBL gene (NCBI Reference Sequence: NM_003811.4) was used as a reference, the 540th T base of its CDS was selected, and primers were designed to mutate it to a C base through PCR. The designed primers are as follows:

[0160] Pr (SEQ ID No. 8):

[0161] 5′-TATAGGCGCGCCTTATTCCGACCTCGGTGAAGGGAG-3′ (containing the Sgs I restriction enzyme site);

[0162] At the same time, synonymous mutation primers were designed and synthesized with the 540th base of the coding sequence as the center:

[0163] Pf12 (SEQ ID No. 9):

[0164] 5'-GCTGCTGGGGCCGCCGCCCTGGCCTTGACCGTGGACCTGCCACCCG-3'.

[0165] Using the wild-type human 4-1BBL gene (H4-1BBL) as a template and Pf12 and Pr as primers, fragment F1-1 was obtained by PCR (technical route see Figure 3 PCR product fragments are shown in Figure 5 ).

[0166] In order to connect the F1-1 and F1-2 fragments containing the mutated base into a full-length human 4-1BBL gene containing the mutation, the F1-1 and F1-2 fragments were used as templates, Pf and Pr were used as primers, and PCR was used to obtain a full-length human 4-1BBL gene fragment containing a mutation at position 540 to a C base. Compared with the wild-type human 4-1BBL gene coding sequence (CDS), the obtained fragment had a change at position 540 of the CDS. Since the sequence of the polypeptide product encoded by it was not changed at the third position of the codon to which it belongs, it is called a 4-1BBL gene with a synonymous mutation and is named mH4-1BBL (see the technical route). Figure 4 PCR product fragments are shown in Figure 5 ).

[0167] Primer information is as follows:

[0168] Pf (SEQ ID No. 10):

[0169] 5'-TATAGTCGACATGGAATACGCCTCTGACGCTTC-3' (containing the Sal I restriction enzyme site);

[0170] Pr (SEQ ID No. 11):

[0171] 5'-TATAGGCGCGCCTTATTCCGACCTCGGTGAAGGGAG-3' (containing the Sgs I restriction enzyme site).

[0172] 2. Design and preparation process of synonymous mutations at G base 468 and C base 597 in CDS of human 4-1BBL gene:

[0173] In order to prove the universality of the effect of synonymous mutation of 4-1BBL gene in this example, a method similar to Figure 2 , Figure 3 and Figure 4 In the process shown, the 468th G base and the 597th C base of the coding sequence of the wild-type human 4-1BBL gene (gene sequence is NCBI Reference Sequence: NM_003811.4) were selected for synonymous mutations. The details are as follows:

[0174] 1) Design synonymous mutation primers centered on the 468th base of the coding sequence:

[0175] Pr21 (SEQ ID No. 12):

[0176] 5'-CAAGTGAAACGGAGCCTGAGCCTTCGCCGGCCACCACGCGC-3';

[0177] Pf22 (SEQ ID No. 13):

[0178] 5'-GCGCGTGGTGGCCGGCGAAGGCTCAGGCTCCGTTTCACTTG-3'.

[0179] Using the wild-type human 4-1BBL gene as a template, Pf and Pr21 as a primer pair, and Pf22 and Pr as a primer pair, the 468 synonymous mutant base (the 468 G base mutated to the 468 A base, and the corresponding codon still encoded glutamate) was introduced into the human 4-1BBL gene fragment by high-fidelity PCR, and the PCR product fragments F2-1 and F2-2 (such as Fig.13 ). Using fragments F2-1 and F2-2 as templates, and using F and R as genes, fragments F2-1 and F2-2 were connected to form a complete human 4-1BBL gene with a synonymous mutation at position 468. The above-mentioned mutation at position 468 did not change the sequence of the polypeptide product encoded by it. The 4-1BBL gene after the synonymous mutation was named mH4-1BBL-2 gene (PCR product fragment see Figure 5 ).

[0180] 2) Design synonymous mutation primers centered on the 597th base of the coding sequence:

[0181] Pr31 (SEQ ID No. 14):

[0182] 5'-GGTGCAGCAAGCGGCCCTGAAAACCGAAGGCCGAGTTCCG-3';

[0183] Pf32 (SEQ ID No. 15):

[0184] 5'-CGGAACTCGGCCTTCGGTTTTCAGGGCCGCTTGCTGCACC-3'.

[0185] Using the wild-type human 4-1BBL gene as a template, Pf and Pr31 as primers, and Pf32 and Pr as primers, a synonymous mutation base at position 597 (base C at position 597 mutated to base T at position 597, and the corresponding codon still encodes phenylalanine) was introduced into the human 4-1BBL gene fragment by high-fidelity PCR, and the PCR product fragments F3-1 and F3-2 ( Fig.13). Using fragments F3-1 and F3-2 as templates, and using F and R as genes, fragments F3-1 and F3-2 were connected to form a complete human 4-1BBL gene with a synonymous mutation at position 597. The above-mentioned 597-base mutation did not change the sequence of the polypeptide product encoded by it. The 4-1BBL gene after the synonymous mutation was named mH4-1BBL-3 gene (PCR product fragment see Figure 5 ).

[0186] 3. Preparation of synonymous mutant human 4-1BBL homologous recombination vector:

[0187] The vector PV-1, mH4-1BBL gene, mH4-1BBL-2 gene and mH4-1BBL-3 gene were double-digested with Sal I and Sgs I restriction enzymes, respectively. After 1% gel electrophoresis, the gel was cut and the target fragments were recovered. The digested vector PV-1 backbone was ligated with the recovered mH4-1BBL gene, mH4-1BBL-2 gene and mH4-1BBL-3 gene using T4 ligase (connected overnight at 4°C), the ligation products were transformed into DH5α competent Escherichia coli, spread on an LB plate containing 100 μg / mL ampicillin, and cultured at 37°C for 16 hours to select resistant colonies, extract recombinant plasmids, and confirm by gene sequencing that the mH4-1BBL gene, mH4-1BBL-2 gene and mH4-1BBL-3 gene were correctly cloned into the homologous recombination vector PV-1, and the above recombinant plasmids were named PV-mH4-1BBL, PV-mH4-1BBL-2 and PV-mH4-1BBL-3, respectively.

[0188] 3. Preparation of synonymous mutant human 4-1BBL recombinant oncolytic virus:

[0189] PV-mH4-1BBL, PV-mH4-1BBL-2 and PV-mH4-1BBL-3 were respectively infected with vaccinia virus (VV) to obtain recombinant oncolytic viruses.

[0190] Take CV1 cells in the logarithmic growth phase and adjust the cell density to 1×10 5 / mL, inoculated into 24-well plates at 1mL / well. 24h later, CV1 cells were infected with vaccinia virus (VV). 2h after infection, PV-mH4-1BBL, PV-mH4-1BBL-2 and PV-mH4-1BBL-3 were mixed with transfection reagent (Polyplus, France) and incubated at room temperature for 15min, and 200μL of the mixture was transfected into CV1 cells. 2h later, DMEM medium containing 10% FCS was added and cultured for 48h. The fluorescence intensity of yellow fluorescent protein (YFP) was detected by fluorescence microscopy to determine the homologous recombination of plasmid and virus. After the cells were completely broken, the virus-cell suspension was collected.

[0191] Take CV1 cells in the logarithmic growth phase and adjust the cell density to 1.5×10 5 / mL, inoculated into a 6-well plate at 2mL / well. After 24h, add the virus cell suspension to infect CV1 cells. Culture for 24h, digest the CV1 cells, and use flow cytometry to sort the CV1 cells expressing YFP to prepare a single cell suspension. By limiting dilution, YFP+CV1 cells were inoculated into a 96-well plate pre-plated with CV1 cells. After 48h, select the culture wells with a single YFP+ virus plaque, collect the cells and supernatant, and obtain the virus suspension after repeated freezing and thawing for use.

[0192] The virus suspension obtained above was used to infect 293T cells expressing cre enzyme, and the YFP gene in the recombinant VV genome was excised, and then the monoclonal recombinant VV was screened to obtain the seeds of the target recombinant VV and purify it. Through gene sequencing analysis, it was confirmed that the synonymous mutant human 4-1BBL gene mH4-1BBL, mH4-1BBL-2 and mH4-1BBL-3 genes were recombined into VV. The recombinant oncolytic poxviruses inserted with the synonymous mutant human 4-1BBL gene mH4-1BBL, mH4-1BBL-2 and mH4-1BBL-3 were named VV-mH4-1BBL, VV-mH4-1BBL-2 and VV-mH4-1BBL-3.

[0193] Hela cells were cultured in a culture dish with a diameter of 15 cm. When the abundance of Hela cells was about 80%, the virus cell suspension was added to infect the Hela cells, and the infection was amplified until sufficient virus cell suspension was obtained.

[0194] Purification of recombinant poxvirus: Collect the virus cell suspension, centrifuge and discard the supernatant. Freeze and thaw 3 times to lyse the cells, grind the cells with a Dounce homogenizer to release the virus particles. Centrifuge at 1200r / min to collect the virus-containing supernatant, add it to the top of the 36% sucrose solution, centrifuge at 130000×g for 1h, resuspend the obtained precipitate with 10mM Tris-HCl and freeze it for later use.

[0195] In order to confirm whether the synonymous mutant human 4-1BBL recombinant poxvirus constructed above can express 4-1BBL molecules on the surface of tumor cells after infecting tumor cells, the above virus was used to infect human colorectal cancer cell lines, and the expression of 4-1BBL molecules on the cell surface was detected by immunofluorescence labeling and flow cytometry analysis, as follows:

[0196] Human colorectal cancer cell line HCT-116 in logarithmic growth phase was selected and the cell density was adjusted to 3×10 5 / mL, inoculate 1mL to a 24-well plate. After the cells are completely attached, they are divided into VV-ΔTK, VV-mH4-1BBL, VV-mH4-1BBL-2 and VV-mH4-1BBL-3 infection groups, and are infected separately according to a multiplication of infection (MOI) of 1. After 24 hours, the infected cells were collected and stained with APC-labeled anti-human 4-1BBL monoclonal antibody, and the expression of cell membrane 4-1BBL molecules was analyzed by flow cytometry. The results showed that the 4-1BBL molecules were not expressed on the surface of HCT-116 cells infected with the vaccinia virus VV-ΔTK in which only the tk gene was deleted, and the 4-1BBL molecules were expressed at high levels on the surface of HCT-116 cells infected with VV-mH4-1BBL, VV-mH4-1BBL-2 and VV-mH4-1BBL-3 ( Figure 6 ).

[0197] Figure 6 In the expression, VV-ΔTK: recombinant vaccinia virus with tk gene deleted; VV-mH4-1BBL: recombinant vaccinia virus with tk gene deleted and mH4-1BBL gene fragment inserted; VV-mH4-1BBL-2: recombinant vaccinia virus with tk gene deleted and mH4-1BBL-2 gene fragment inserted; VV-mH4-1BBL-3: recombinant vaccinia virus with tk gene deleted and mH4-1BBL-3 gene fragment inserted; Anti-4-1BBL-APC: APC-labeled anti-human 4-1BBL monoclonal antibody.

[0198] 4. Synonymous mutations: Detection of synonymous mutation sites by molecular biological methods after tumor cells are infected with human 4-1BBL recombinant oncolytic poxvirus:

[0199] In order to verify whether the exogenous 4-1BBL introduced after the synonymous mutant human 4-1BBL recombinant oncolytic poxvirus infected tumor cells can be detected, the recombinant oncolytic viruses VV-mH4-1BBL, VV-mH4-1BBL-2 and VV-mH4-1BBL-3 were used to infect the human intestinal cancer cell line HCT-116, and an uninfected group was set up as a control. Then RT-PCR detection and analysis were performed, as follows:

[0200] According to the above method, VV-mH4-1BBL, VV-mH4-1BBL-2 and VV-mH4-1BBL-3 were infected with human intestinal cancer cell line HCT-116 at MOI=1, and an uninfected group was set up at the same time. After 24 hours, the cells were collected and placed in 200μL Trizol solution for lysis and total RNA was extracted. The RNA was reverse transcribed into cDNA using Takara's RT-PCR kit. At the same time, total RNA of uninfected HCT116 cells was extracted and reverse transcribed to obtain cDNA.

[0201] Primers were designed in the CDS region of the human 4-1BBL gene (gene sequence with NCBI Reference Sequence: NM_003811.4) covering the mutation site. The primer sequences are as follows:

[0202] Pif (SEQ ID No. 16): 5'-TGAGCTACAAAGAGGACACGAAGGAGC-3';

[0203] PiR (SEQ ID No. 17): 5'-TTATTCCGACCTCGGTGAAGGGAGTCC-3'.

[0204] Using the obtained cDNA as a template, Pif and PiR as primers, a human 4-1BBL gene fragment covering the synonymous mutation site was amplified by PCR, and the PCR product was connected to the pUMc-T vector and transformed into competent DH5α Escherichia coli, and then spread on an ampicillin-resistant LB plate. After the resistant colonies were formed, a single colony was randomly selected for unidirectional sequencing. The sequencing primer sequence was 5'-GTTGTAAAACGACGGCCAG-3' (SEQ ID No. 18). The results are as follows:

[0205] Five colonies were selected from the uninfected group to extract plasmids and then sequenced. The results are as follows: Figure 7 As shown, the BLAST program on the NCBI website shows that the fragments covered by primers Pif and Pir are 100% matched with the CDS region of the human 4-1BBL gene (NCBI Reference Sequence: NM_003811.4) ( Figure 8). This result confirmed that the human 4-1BBL gene expressed by colorectal cancer cells had no mutation.

[0206] 1) 10 colonies from the VV-mH4-1BBL infection group were selected for unidirectional sequencing. The results showed that a total of 10 colonies were successfully sequenced, and all detected Fig. 9 The synonymous mutations indicated by the arrows in the figure, while no mutations were found at other sites. This result shows that VV-mH4-1BBL can replicate in large quantities after infecting tumor cells, and the synonymous mutations it carries (the 540th T base mutates to the 540th C base) can be clearly detected. Therefore, the synonymous mutations of human 4-1BBL can provide a means for detecting and identifying the introduction of exogenous human 4-1BBL genes without changing their encoded amino acid sequences.

[0207] 2) 10 colonies from the VV-mH4-1BBL-2 infection group were selected for unidirectional sequencing. The results showed that a total of 10 colonies were successfully sequenced, and all detected Fig.10 The synonymous mutations marked by the arrows in the figure, while no mutations were found at other sites. This result shows that VV-mH4-1BBL can replicate in large quantities after infecting tumor cells, and the synonymous mutation 468 base (the 468 G base mutates to the 468 A base) it carries can be clearly detected. Therefore, the synonymous mutation of human 4-1BBL can provide a means for detecting and identifying the introduction of exogenous human 4-1BBL gene without changing its encoded amino acid sequence.

[0208] 3) 10 colonies from the VV-mH4-1BBL-2 infection group were selected for unidirectional sequencing. The results showed that a total of 10 colonies were successfully sequenced, and all detected Fig.11 The synonymous mutations marked by the arrows in the figure, while no mutations were found at other sites. This result shows that VV-mH4-1BBL can replicate in large quantities after infecting tumor cells, and the synonymous mutation 597 base (the 597 C base mutates to the 597 T base) it carries can be clearly detected. Therefore, the synonymous mutation of human 4-1BBL can provide a means for detecting and identifying the introduction of exogenous human 4-1BBL gene without changing its encoded amino acid sequence.

[0209] Example 3

[0210] Anti-tumor effect of synonymous mutation 4-1BBL recombinant poxvirus and detection of synonymous mutation sites:

[0211] In order to further verify the anti-tumor effect of the synonymous mutation 4-1BBL recombinant poxvirus and verify the detection of the synonymous mutation site 4-1BBL during its treatment, this example constructed a synonymous mutant based on mouse 4-1BBL, and constructed a synonymous mutation mouse 4-1BBL oncolytic vaccinia virus. At the same time, a peritoneal mouse intestinal cancer model was established for experimental treatment and the synonymous mutation site of mouse 4-1BBL was detected during the treatment. The specific implementation process is as follows:

[0212] 1. Construction of synonymous mutant mouse 4-1BBL gene recombinant vector and synonymous mutant mouse 4-1BBL recombinant oncolytic vaccinia virus:

[0213] In order to verify that the mutant human 4-1BBL gene expressed by tumor cells infected with the synonymous mutant human 4-1BBL recombinant poxvirus can be detected by molecular biological methods, a synonymous mutant mouse 4-1BBL gene was constructed by a similar method as in Example 2 and cloned into the homologous recombination vector PV-1 ( Fig.12 ), named PV-4-1BBL. The results of gene sequencing are as follows Fig.13 The obtained sequence was compared with the CDS of mouse 4-1BBL gene (NCBI Reference Sequence ID: NM_009404.3) by BLAST program on NCBI website, and the results showed that the C base at position 309 of CDS of 4-1BBL gene in PV-4-1BBL was mutated to T base ( Fig.14 The corresponding codon ACC is mutated to ACT, but the encoded products of both are still threonine. Therefore, a homologous recombination vector based on the synonymous mutant mouse 4-1BBL gene (referred to as 4-1BBL in this example) was successfully established.

[0214] A similar method as in Example 2 was used to recombinantly introduce the synonymous mutant 4-1BBL gene into the oncolytic poxvirus using PV-4-1BBL, and simultaneously knock out its tk gene to establish a recombinant oncolytic virus named VV-ΔTK-4-1BBL. The anti-tumor function of VV-ΔTK-4-1BBL was verified by in vitro and in vivo experiments, and the synonymous mutation sites of 4-1BBL were detected.

[0215] Fig.12 PV-4-1BBL in: a recombinant vector in which the synonymous mutant mouse 4-1BBL gene was introduced into the multiple cloning site of the PV-1 vector.

[0216] 2. RT-PCR was used to detect the expression of 4-1BBL at the mRNA level after VV-ΔTK-4-1BBL infected colorectal cancer cells:

[0217] In order to detect the expression of 4-1BBL gene after VV-ΔTK-4-1BBL infected tumor cells, the intestinal cancer cell line MC-38 cells were selected as a model, and VV-ΔTK-4-1BBL was infected with MC-38 cells at an infection multiplicity of 1, and the VV-ΔTK infection group was set as a control. Tumor cells were collected 24 hours after infection, total RNA was extracted and reverse transcribed into cDNA, and the 4-1BBL gene was amplified by PCR.

[0218] The experimental results show that ( Fig.15 ), the target gene band of the VV-△TK-4L infection group was highlighted, and the VV-△TK infection group and the non-infection group only had the background level target gene band. This result confirmed that after VV-△TK-4-1BBL infected tumor cells, high levels of 4-1BBL gene were expressed with the help of rapid viral replication, and also proved that tumor cells had background levels of 4-1BBL gene expression (previous studies by the applicant found that the protein encoded by this gene was expressed in the tumor cell membrane without intervention).

[0219] After MC-38 cells were infected with the recombinant oncolytic poxvirus VV-ΔTK-4-1BBL, the results of high expression of the 4-1BBL gene detected by RT-PCR were as follows: Fig.15 As shown, wherein, lane M: DL 2000 DNA Marker; lane 1: uninfected group; lane 2: VV-ΔTK infected group; lane 3: uninfected group; lane 4: VV-ΔTK-4-1BBL infected group.

[0220] 3. Flow cytometry detection of 4-1BBL expression on the surface of colorectal cancer cells after VV-ΔTK-4-1BBL infection:

[0221] In order to confirm whether the rapid replication of recombinant oncolytic viruses in tumor cells can achieve high expression of 4-1BBL molecules and localize them on the surface of tumor cells, the colorectal cancer cell line MC-38 in the logarithmic growth phase was infected with different viral infection multiplicity (MOI) of 0, 0.1, 1, and 5. The cells were digested after 24 hours to prepare single cell suspensions, which were stained with fluorescein-labeled anti-4-1BBL monoclonal antibodies and analyzed by flow cytometry for the expression of cell membrane 4-1BBL.

[0222] Experimental results ( Fig.16 ) showed that with the increase of virus infection multiplicity (MOI), the expression of yellow fluorescent protein (YFP) carried by the recombinant virus increased; the VV-△TK-4L infection group expressed cell membrane 4-1BBL, and the expression increased with the increase of MOI; the VV-△TK infection group did not express cell membrane 4-1BBL. This result confirmed that VV-△TK-4-1BBL infection of tumor cells can achieve the expression of 4-1BBL molecules on the surface of tumor cells.

[0223] 4. Virus titer method to detect the proliferation ability of VV-ΔTK-4-1BBL in different tumor cells:

[0224] To confirm the effect of gene recombination on the ability of vaccinia virus to replicate and proliferate in tumor cells, LTPA cells, B16-F10 cells, Panc02 / Luc cells and MC-38 cells were infected with each recombinant virus, and the cells were collected 24h, 48h and 72h after infection, and then infected with green monkey kidney cells CV-1 after repeated freezing and thawing and dilution. The virus yield was determined by the plaque lysis method.

[0225] Experimental results ( Fig.17 ) showed that after the 4-1BBL gene was recombined into the vaccinia virus, it did not change the replication characteristics of the virus itself in tumor cells.

[0226] 5. Detection and comparison of the killing ability of VV-ΔTK-4-1BBL on tumor cells:

[0227] In order to confirm whether the gene recombination in this example affects the viral oncolytic effect, in this experiment, each recombinant virus was infected with LTPA cells, B16-F10 cells, Panc02 / Luc cells and MC-38 cells at different MOIs (0, 0.1, 0.5 and 5), and the proportion of live cells was detected by MTT method after 48 hours.

[0228] Experimental results ( Fig.18 ) showed that the oncolytic activity of the virus itself was not changed after the 4-1BBL gene was recombined into the vaccinia virus.

[0229] 6. Detection of synonymous mutation sites of 4-1BBL during tumor treatment with recombinant oncolytic poxvirus:

[0230] In order to verify whether the synonymous mutation 4-1BBL recombinant oncolytic poxvirus can be detected during tumor treatment, VV-ΔTK-4-1BBL was used for experimental treatment based on the establishment of a mouse intestinal cancer model, and then tumor tissues were taken for detection. The specific process is as follows.

[0231] Select 8-12 week old C57BL / 6 mice and sample them at 5×10 5 / mice were intraperitoneally inoculated with MC-38 colorectal cancer cells. Nine days later, the mice were randomly divided into two groups. One group was divided into two groups. 8 PFU / mouse were intraperitoneally injected with VV-ΔTK-4L, and another group was intraperitoneally injected with an equal amount of PBS. After 48 hours, the mice were taken out and killed, and the tumor tissue was taken out. 10 mg of tumor tissue was dissolved in Trizol and total RNA was extracted. After reverse transcription into cDNA, PCR was used.

[0232] Primers were designed based on the CDS region of the mouse 4-1BBL gene (NCBI Reference Sequence ID: NM_009404.3). The primer sequences are as follows:

[0233] Pmf (SEQ ID No. 19):

[0234] 5'-TATAAAGCTTATGGACCAGCACACACTTGATG-3';

[0235] Pmr (SEQ ID No. 20):

[0236] 5'-TATATCTAGATCATTCCCATGGGTTGTCGG-3'.

[0237] The obtained cDNA was used as a template, Pmf and PmR were used as primers, and the full-length fragment covering the mouse 4-1BBL gene CDS was amplified by PCR. The PCR product was connected to the pUMc-T vector and transformed into competent DH5α Escherichia coli, and then spread on an ampicillin-resistant LB plate. After the resistant colonies were formed, a single colony was randomly selected for unidirectional sequencing. The sequencing primer sequence was 5'-GTTGTAAAACGACGGCCAG-3' (SEQ ID No. 21).

[0238] The experimental results showed that in the PBS treatment group, three clones were randomly selected for sequencing, and the 4-1BBL fragments obtained were all wild-type 4-1BBL, that is, 100% matching the CDS region of the mouse 4-1BBL gene (NCBI Reference Sequence ID: NM_009404.3) ( Fig.19 and Fig. 20 ), Fig.19 In the figure, the arrow indicates that there is no mutation at the 309th C base of the mouse 4-1BBL gene CDS; in the VV-△TK-4-1BBL group, 10 clones were randomly selected for sequencing, and the 4-1BBL sequence in one clone had a 100% match with the CDS region of the mouse 4-1BBL gene (NCBI Reference Sequence ID: NM_009404.3), while the other 9 clones were detected to have a mutation of the 309th C base of the CDS to a T base, while there was no mutation at the other sites ( Fig.21 and Fig. 22 ), Fig.21 In the figure, the arrow indicates that the C base at position 309 of the CDS of the mouse 4-1BBL gene mutated to a T base. Fig. 22In the figure, the arrow indicates that the 309th C base of the mouse 4-1BBL gene CDS mutated to a T base. The wild-type 4-1BBL gene comes from tumor-bearing mice, while a high proportion of synonymous mutant 4-1BBL gene expression originates from the oncolytic virus VV-△TK-4-1BBL.

[0239] This result proves that tumor cells have background levels of 4-1BBL gene expression, and also confirms that during in vivo treatment with VV-△TK-4-1BBL, after infecting tumor cells, the virus rapidly replicates and expresses high levels of synonymous mutant 4-1BBL genes, which can be detected by molecular biological methods.

[0240] VII. Detection of the effects and mechanisms of the synonymous mutation 4-1BBL recombinant oncolytic poxvirus on peripheral immune organs:

[0241] 1. In order to comprehensively investigate the in vivo anti-tumor effect and mechanism of action of VV-ΔTK-4-1BBL and verify the effect of VV-ΔTK-4-1BBL on peripheral immune tissues and organs, 8-12 week old C57BL / 6 mice were selected and cultured at 5×10 5 / mice were intraperitoneally inoculated with MC-38 colorectal cancer cells. 9 days later, the mice were randomly divided into groups and divided into 2×10 8 PFU / mouse were intraperitoneally injected with VV-ΔTK-4L, VV-ΔTK and an equal volume of PBS. The mice were killed 5 days later, and the spleens of the mice were weighed and single cell suspensions were prepared and counted.

[0242] Experimental results ( Fig.23 ) showed that VV-ΔTK-4-1BBL treatment of MC-38 tumor-bearing mice could induce spleen weight ( Fig.23 A) and spleen cell count ( Fig.23 B), which can promote the proliferation of peripheral immune cells and the proliferation of peripheral immune tissues and organs.

[0243] Experimental results ( Fig.24 ) showed that VV-ΔTK-4-1BBL treatment of MC-38 tumor-bearing mice promoted the expression of CD3+T cells in spleen cells ( Fig.24 A) CD4+T cells ( Fig.24 B) and CD8+ T cells ( Fig.24 C) The ratio increased. This confirms that VV-ΔTK-4-1BBL can promote the proliferation of T cells and their subsets and NK cells in peripheral immune tissues and organs through the combined action of oncolytic viruses and the 4-1BBL molecules they express.

[0244] 2. In order to comprehensively investigate the in vivo anti-tumor effect and mechanism of action of VV-ΔTK-4-1BBL and verify the effect of VV-ΔTK-4-1BBL on the expression of PD-1 and other immune checkpoint molecules by CD4+T and CD8+T cells, which are key cells of anti-tumor immunity, 8-12 week old C57BL / 6 mice were selected and cultured at 5×10 5 / mice were intraperitoneally inoculated with MC-38 colorectal cancer cells. 9 days later, the mice were randomly divided into groups and divided into 2×10 8 PFU / mouse were intraperitoneally injected with VV-ΔTK-4L, VV-ΔTK and an equal volume of PBS. The mice were killed 5 days later, and the spleens of the mice were obtained to prepare single cell suspensions, which were then analyzed by immunofluorescence staining and flow cytometry.

[0245] Experimental results ( Fig.25 ) showed that VV-ΔTK-4-1BBL produced an anti-tumor immune response after treating tumors, which could feedback-regulate the expression of PD-1 molecules on the surface of immune cells such as CD4+T and CD8+T. This result shows that the concept of VV-ΔTK-4-1BBL combined with PD-1 / PD-L1 pathway blockers to improve anti-tumor efficacy has a necessary prerequisite.

[0246] 8. Detection of the effects and mechanisms of synonymous mutation 4-1BBL recombinant oncolytic poxvirus on the tumor microenvironment:

[0247] 1. In order to verify the effect of VV-ΔTK-4-1BBL on the anti-tumor immune status in the tumor microenvironment, 8-12 week old C57BL / 6 mice were selected and cultured at 5×10 5 / mice were intraperitoneally inoculated with MC-38 colorectal cancer cells. 9 days later, the mice were randomly divided into groups and divided into 2×10 8 PFU / mouse were intraperitoneally injected with VV-ΔTK-4L, VV-ΔTK and an equal volume of PBS. The mice were killed 5 days later, and the tumor tissues were obtained to prepare single cell suspensions, which were analyzed by immunofluorescence staining and flow cytometry.

[0248] Experimental results ( Fig.26 ) showed that after VV-ΔTK-4-1BBL treated MC-38 tumor-bearing mice, the proportion of CD3+T, CD8+T, and CD4+T cells in tumor tissues increased significantly. This suggests that VV-ΔTK-4-1BBL can promote the increase in the number of T cells and their subpopulations in tumor tissues and change the anti-tumor immune situation through the combined action of oncolytic viruses and the 4-1BBL molecules they express.

[0249] 2. In order to verify the effect of VV-ΔTK-4-1BBL on the anti-tumor immune status in the tumor microenvironment, 8-12 week old C57BL / 6 mice were selected and 5×10 5 / mice were intraperitoneally inoculated with MC-38 colorectal cancer cells. 9 days later, the mice were randomly divided into groups and divided into 2×10 8 PFU / mouse were intraperitoneally injected with VV-ΔTK-4L, VV-ΔTK and an equal volume of PBS. The mice were killed 5 days later, and 50 mg of each tumor tissue was dissolved in Trizol to extract total RNA, which was reverse transcribed into cDNA and analyzed by Realtime PCR (real-time quantitative PCR).

[0250] Experimental results ( Fig. 27 ) showed that the anti-tumor immune molecules such as perforin, granzyme B, IFN-γ, IL-1β, TNF-α in the tumor tissue of the VV-ΔTK-4-1BBL treatment group were significantly increased, while negative immune molecules such as TGF-β were significantly reduced compared with the blank oncolytic virus control (VV-ΔTK) group. These results further prove that VV-ΔTK-4-1BBL can work together through oncolytic viruses and the 4-1BBL molecules they express to change the immune situation in tumor tissues and promote anti-tumor immune effects.

[0251] IX. Verification of the in vivo anti-tumor effect of the synonymous mutation 4-1BBL recombinant oncolytic poxvirus:

[0252] In this embodiment, the 4-1BBL gene was recombined into the vaccinia virus genome to construct a new recombinant vaccinia virus. In order to compare its anti-tumor ability in vivo, in this experiment, mouse intestinal cancer cells MC-38 were injected into the abdominal cavity of C57 / BL6 mice to establish an intestinal cancer abdominal tumor model. After 9 days, the mice were randomly divided into groups and injected with each recombinant virus into the abdominal cavity, and then the survival time of the mice was observed. The results showed that compared with the phosphate buffer treatment group (PBS), the survival time of tumor-bearing mice in the VV-ΔTK (VV with TK gene knocked out) and VV-ΔTK-4-1BBL (VV with TK gene knocked out and 4-1BBL gene recombined) treatment groups was prolonged compared with the PBS treatment group, and the survival time of tumor-bearing mice in the VV-ΔTK-4-1BBL treatment group was prolonged compared with the VV-ΔTK treatment group.

[0253] Experimental results ( Fig.28 ) showed that VV-ΔTK-4-1BBL can produce significant anti-tumor effects when used to treat tumors and prolong the survival time of the treated subjects.

[0254] 10. Verification of the in vivo anti-tumor effect of the synonymous mutation 4-1BBL recombinant oncolytic poxvirus combined with PD-1 monoclonal antibody:

[0255] In order to verify the combined therapeutic effect of VV-ΔTK-4-1BBL combined with immune checkpoint blockers, in this experiment, mouse colorectal cancer cells MC-38 were injected into the peritoneal cavity of C57 / BL6 mice to establish a colorectal cancer peritoneal tumor model. After 9 days, the mice were randomly divided into 4 groups: PBS treatment group, VV-ΔTK-4-1BBL, PD-1 blocking monoclonal antibody treatment group, and VV-ΔTK-4-1BBL combined with PD-1 blocking monoclonal antibody treatment group. They were treated with intraperitoneal injections and the survival time of the mice was observed.

[0256] Experimental results ( Fig.29 ) showed that the survival time of tumor-bearing mice in the VV-ΔTK-4-1BBL and PD-1 blocking mAb treatment groups was longer than that in the PBS treatment group, while the efficacy of tumor-bearing mice in the VV-ΔTK-4-1BBL and PD-1 blocking mAb treatment groups was equivalent. The therapeutic effect of the VV-ΔTK-4-1BBL combined with PD-1 blocking mAb treatment group was significantly better than that of the VV-ΔTK-4-1BBL treatment group or the PD-1 blocking mAb treatment group.

[0257] This result proves that VV-ΔTK-4-1BBL can provide a powerful means to improve the efficacy of immune checkpoint blockers such as PD-1 monoclonal antibodies in treating tumors. The combination of VV-ΔTK-4-1BBL and immune checkpoint blockade can produce more obvious anti-tumor effects and improve the survival rate and survival time of treated subjects.

[0258] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A recombinant oncolytic vaccinia virus, characterized in that: The recombinant oncolytic vaccinia virus is operably inserted into a synonymous mutated exogenous gene capable of expressing 4-1BBL; The foreign gene is inserted into the TK gene of vaccinia virus; The DNA sequence of the exogenous gene is shown in SEQ ID No.1-SEQ ID No.3; The exogenous gene is connected via an IRES sequence, and the IRES sequence is shown in SEQ ID No.

5.

2. The recombinant oncolytic vaccinia virus according to claim 1, characterized in that The amino acid sequence of the exogenous gene is shown in SEQ ID No.

4.

3. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the recombinant oncolytic vaccinia virus as described in claim 1 or 2, a pharmaceutically acceptable carrier and a pharmaceutical excipient, and a PD-1 monoclonal antibody that can be used in combination with the recombinant oncolytic vaccinia virus.

4. The pharmaceutical composition according to claim 3, characterized in that The pharmaceutical composition is administered by direct injection and / or combined with endoscopic injection.

5. The pharmaceutical composition according to claim 4, characterized in that The endoscopes selected are laparoscope, choledochoscope, thoracoscope, enteroscope and neuroendoscope.

6. Use of the recombinant oncolytic vaccinia virus according to claim 1 or 2, or the pharmaceutical composition according to claim 3 or 4 in the preparation of a medicament for preventing or treating colon cancer.